MEDIPOST obtained Japan patent for stem cell related technology which can be utilized in development of treatment for Altzheimer’s dementia.

MEDIPOST disclosed on 17 April that they obtained patent from the Japan Office of Patents in relation to ‘Pharmaceutical Composition for Target Treatment’ applying the fact that stem cell has tropism function of investigating/tracking the disease affected part.

The title of this patent is ‘Composition for the diagnosis, prevention or treatment of disease related to cells expressing IL-8 or GRO-alpha, comprising UCB-MSCs’. In relation to such, MEDIPOST personnel explained that “this patent technology will be applied to development of ‘NEUROSTEM^®’ which is a Altzheimer’s dementia treatment drug currently under clinical trial.

Other than this, this patented technology may be utilized for prevention, treatment, diagnosis, and treatment progress observation of brain tumor.